New drug-eluting stents: technological refinement continues
The arrival of drug-eluting stents (DES) nearly 2 decades ago ignited a revolution in the field of interventional cardiology. The addition of antiproliferative drugs to the stent platform reduced the rate of in-stent restenosis significantly and increased the number of patients that, to this date, h...
Guardado en:
Autores principales: | Javier Suárez de Lezo, Pedro Martín |
---|---|
Formato: | article |
Lenguaje: | EN ES |
Publicado: |
Permanyer
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/626637bdb4554f3cbe5e3a267662bc8a |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Nuevos stents farmacoactivos: el refinamiento tecnológico continúa
por: Javier Suárez de Lezo, et al.
Publicado: (2021) -
A Case of Stent Fracture and Very Late Stent Thrombosis 15 Months after Drug-Eluting Stent Implantation
por: A Ghaemian,, et al.
Publicado: (2009) -
Long-term effectiveness and safety of sirolimus drug-eluting stents
por: Bikkina M, et al.
Publicado: (2011) -
Everolimus-eluting coronary stents
por: Alejandro Saez, et al.
Publicado: (2010) -
Advances in drug eluting stents – focus on the Endeavor® zotarolimus stent
por: Jonathan Bridges, et al.
Publicado: (2008)